Biotech Values

[gym gravity]

thanks dew, does anyone disagree with this number:

"
About one in four of 370 publicly held U.S. biotechnology companies has less than six months' cash on hand, according to the Biotechnology Industry Organization, a Washington-based trade group.

``Disarray'' among biotech companies in a tough economic climate works to Amgen's advantage, said Jordan Schreiber, managing director of BlackRock Investment Management's Healthcare Fund, which holds 4.8 million shares. Acquisitions could help Amgen reignite sales and broaden its product pipeline, he said in a telephone interview.

"